今日看点 ▼聚焦一：思林杰：终止发行股份及支付现金购买资产并募集配套资金事项 公司原拟通过发行股份及支付现金的方式购买科凯电子的股权同时配套募集资金，本次交易预计构成重大资产重组且构成 关联交易，不构成重组上市。由于本次交易规模较大、涉及相关方较多，使得重大资产重组方案论证历时较长。现公司综 合考虑市场环境较本次交易筹划初期已发生一定变化，经公司与交易各相关方友好协商、认真研究和充分论证，基于审慎 性考虑，决定终止本次交易事项并向上海证券交易所申请撤回本次交易事项的相关申请文件。 | 条 开 | 公司 | 主要内容 | | --- | --- | --- | | | 五矿新能 | 2025年度预盈2.1亿至2.5亿元 同比扭亏 | | | 招金黄金 | 2025年度预盈1.22亿至1.82亿元 同比扭亏 | | | 优博讯 | 2025年度预盈7200万元至1.07亿元 同比扭亏 | | | 厦门信达 | 2025年度预盈1500万元 同比扭亏 | | | 新强联 | 2025年净利润同比预增1093.07%-1307.21% | | | 永创智能 | 2025年净利润同比预增721.57%-894.86% ...

数据来源：国家统计局，智研咨询整理 知前沿，问智研。智研咨询是中国一流产业咨询机构，十数年持续深耕产业研究领域，提供深度产业研 究报告、商业计划书、可行性研究报告及定制服务等一站式产业咨询服务。专业的角度、品质化的服 务、敏锐的市场洞察力，专注于提供完善的产业解决方案，为您的投资决策赋能。 根据国家统计局数据可知：2025年12月全国化学原料和化学制品制造业出口货值为504.7亿元，同比增 长0.9%；2025年全国化学原料和化学制品制造业累计出口货值为5580.4亿元，累计同比增长0.5%。 2019年-2025年全国化学原料和化学制品制造业出口货值统计图 上市公司：海南海药（000566），东北制药（000597），亚太实业（000691），通化金马（000766）， 北大医药（000788），力生制药（002393），海普瑞（002399），科伦药业（002422），杭氧股份 （002430），长江健康（002435），誉衡药业（002437），华软科技（002453） 相关报告：智研咨询发布的《2025-2031年中国基础化学原料行业市场供需态势及投资前景研判报告》 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 ■ 二、与会计师事务所沟通情况 证券代码：002393 证券简称：力生制药 公告编号：2026-005 天津力生制药股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日-2025年12月31日 2、预计的业绩： √同向上升 3、业绩预告为区间 本次业绩预告相关数据是公司财务部门初步测算的结果，未经会计师事务所审计。公司已就业绩预告有 关事项与年报审计会计师事务所进行了预沟通，公司与会计师事务所在本报告期的业绩预告方面不存在 分歧。 三、业绩变动原因说明 报告期内，公司持续加大市场拓展力度，产品销售有所提升；加之天士力生物医药产业集团有限公司分 红因素影响，归属于上市公司股东的净利润同比增幅较大。 四、其他相关说明 本次业绩预告是公司财务部门初步核算的结果，具体财务数据以公司披露的2025年度报告为准。敬请广 大投资者审慎决策，注意投资风险。 特此公告。 天津力生制药股份有限公司 董事会 2026年01月24日 ...

重要的消息有哪些 1.中国证监会发布《公开募集证券投资基金业绩比较基准指引》（以下简称《指引》），自2026年3月1 日起施行。《指引》共六章二十一条，主要内容包括：一是突出业绩比较基准的表征作用，强调业绩比 较基准运用的严肃性和稳定性。明确业绩比较基准应当与基金合同约定的核心要素和产品投资风格相匹 配，一经选定不得随意变更。二是强化基金管理人的内部控制和管理。明确业绩比较基准应当由公司管 理层决策确定，基金管理人应当建立健全内控机制和管理体系，加强对基金经理、基金产品投资风格稳 定性的持续管理。三是加强对业绩比较基准的外部约束。明确基金托管人的监督职责，规范基金销售机 构、基金评价机构对业绩比较基准的展示、运用等行为，要求基金管理人、基金销售机构做好投资者教 育等工作。四是严格监管。中国证监会及其派出机构依法对基金管理人、基金托管人、基金销售机构、 基金评价机构及从业人员的违法违规行为进行处理。 2.中国证监会发布行政处罚决定书，认定余韩操纵证券市场行为成立。2019年6月3日至2024年8月15日 期间，余韩控制使用67个证券账户，利用资金优势、持股优势，通过连续买卖、对倒交易等方式，操 纵"博士眼镜"股 ...

Group 1 - JunDa Co., Ltd. announced that the comprehensive cost-effectiveness of perovskite photovoltaic technology in extreme space environments remains to be verified [2][5] - The company has invested 30 million yuan to acquire a 16.67% stake in Starwing Chip Energy, but no formal business agreement has been signed for space photovoltaic projects [2][5] - The technology shows potential advantages in lightweight, low cost, and high radiation resistance, but long-term reliability and cost-effectiveness in space are still uncertain [2][5] Group 2 - Aotewei stated that the "space photovoltaic" sector is still in the early exploration and research phase, with significant uncertainties in the industrialization process [3] - The company emphasized that product development to commercial application requires a considerable period, and the impact of related positive expectations on actual operating performance is highly uncertain [3] Group 3 - Tongyu Communications announced its participation in the A1 round financing of Beijing Blue Arrow Hongqing Technology, investing 30 million yuan for a 1.8293% stake [3] - The company will transition from direct to indirect ownership of Hongqing Technology through a partnership agreement [3] Group 4 - Huajin Technology received approval from the China Securities Regulatory Commission for the issuance of H-shares, planning to issue up to 101,573,100 shares [4] - Trina Solar announced a change in the use of remaining raised funds, reallocating 1.7 billion yuan to a new project for distributed smart photovoltaic power station construction [4][5] Group 5 - Yunnan City Investment plans to publicly transfer a 10.5% stake in Qicai Company with a base price of 293 million yuan [6] - Zijin Mining announced the completion of the second phase of the Giant Dragon Copper Mine, increasing production capacity to 350,000 tons per day [6] Group 6 - Shuaifeng Electric expects a net profit loss of 43 million to 62 million yuan in 2025, with potential delisting risk warnings for its stock [7] - Anqi Yeast plans to invest 222 million yuan in a green manufacturing project for yeast products with an annual output of 12,000 tons [7] Group 7 - Zhengzhou Coal and Electricity announced the cessation of production at the Chaohua Coal Mine due to resource depletion and safety risks, expecting a 311 million yuan impairment loss [8] - Oujing Technology announced partial production line shutdowns at its subsidiaries to reduce losses and operating costs [8] Group 8 - North Car Blue Valley plans to invest in the construction of a high-end platform model industrialization and digital upgrade project with a total investment of 1.991 billion yuan [9] - Jingzhida signed a significant contract worth 1.311 billion yuan for semiconductor testing equipment [9] Group 9 - Yanghe Co. announced a cash dividend plan for 2025-2027, committing to distribute no less than 100% of net profit each year [10] - Yanghe Co. also projected a net profit decline of 62.18% to 68.30% for 2025 due to market adjustments and increased channel inventory [10] Group 10 - Huitong Energy expects a net profit decrease of 69.51% to 75.82% for 2025, primarily due to the absence of non-recurring income from property relocation rewards [11] - Dahua Co. reported a net profit increase of 32.65% for 2025, driven by business optimization and cost control [12] Group 11 - Hangzhou Bank reported a net profit increase of 12.05% for 2025, maintaining a stable non-performing loan ratio [12] - Aotejia expects a net profit increase of 41.85% to 79.67% for 2025, supported by sales growth and cost control measures [12] Group 12 - Shenke Co. anticipates a net profit increase of 65.75% to 98.9% for 2025, benefiting from overseas strategy and revenue growth [13] - Pioneering Technology expects a net profit increase of 50.82% to 109.21% for 2025, driven by product technology iterations and market expansion [13] Group 13 - Shanchuang Technology expects a net profit increase of 81.77% to 134.78% for 2025, fueled by demand for enterprise-level storage products [14] - Anshuo Information anticipates a net profit increase of 52.44% to 98.83% for 2025, with government subsidies contributing to the growth [14] Group 14 - Zhongwei Company expects a net profit increase of 28.74% to 34.93% for 2025, driven by increased customer recognition of its plasma etching equipment [15] - Jingfang Technology anticipates a net profit increase of 44.41% to 52.32% for 2025, benefiting from the automotive industry's growth [16] Group 15 - Fuda Alloy expects a net profit increase of 119.14% to 219.95% for 2025, driven by strong demand in emerging applications [17] - Feirongda anticipates a net profit increase of 57.23% to 83.43% for 2025, supported by stable growth in communication and cooling business [17] Group 16 - Licheng Performing Arts expects a net profit decrease of 12.75% to 32.21% for 2025, impacted by regional travel environment fluctuations [22] - Lisheng Pharmaceutical anticipates a net profit increase of 116.77% to 138.44% for 2025, driven by market expansion and product sales [23] Group 17 - JMC reported a net profit decrease of 22.71% for 2025, despite a 2.07% increase in total revenue [27] - Daoshi Technology expects a net profit increase of 206.01% to 269.76% for 2025, driven by overseas business expansion [28] Group 18 - Jin Kai New Energy plans to repurchase shares worth 500 million to 600 million yuan, with a maximum repurchase price of 7.5 yuan per share [29] - Longyun Co. announced a stock suspension due to plans to acquire a 58% stake in Yuheng Film Industry [30]

力生制药表示，报告期内，公司持续加大市场拓展力度，产品销售有所提升；加之天士力生物医药产业 集团有限公司分红因素影响，归属净利润同比增幅较大。 北京商报讯（记者 丁宁）1月23日晚间，力生制药（002393）发布2025年业绩预告显示，预计2025年实 现归属净利润4亿元至4.4亿元，同比增长116.77%-138.44%。 ...

Market Performance - The three major A-share indices collectively rose on January 23, with over 3,900 stocks closing higher, including 121 stocks hitting the daily limit up [1] - For the week, the Shanghai Composite Index increased by 0.83%, the Shenzhen Component Index rose by 1.11%, while the ChiNext Index fell by 0.34% [2] Weekly Stock Performance - Over 4,200 stocks rose this week, with 35 stocks gaining over 30%. The largest increase was seen in *ST Lifan, which surged by 95.52% [3] - Other notable gainers included *ST K Pharmaceutical and Fenglong Co., which both saw increases exceeding 50% [3] - The power equipment sector had 10 stocks listed among those with over 30% gains, while the machinery and non-ferrous metals sectors had 4 stocks each [3] Top Gainers - The top gainers for the week included: - *ST Lifan: 95.52% increase, closing at 1.31 yuan [4] - *ST K Pharmaceutical: 70.37% increase, closing at 0.92 yuan [4] - Fenglong Co.: 61.08% increase, closing at 99.53 yuan [4] - Other significant gainers included companies in construction decoration and power equipment sectors [4] Weekly Decliners - Among the stocks that declined, 46 stocks fell by over 10%, with Koma Materials dropping over 30% [5] - Other notable decliners included Silin Jie and Bofei Electric, which saw declines of over 24% [5] Institutional Activity - Institutions were active in the market, with 160 stocks appearing on the institutional leaderboard, net buying 102 stocks and net selling 58 stocks [7] - The highest net buying was seen in Shengxin Lithium Energy, which rose by 26.38% with a net institutional purchase of approximately 638.55 million yuan [9] - Other stocks with significant institutional net buying included Quanfeng Technology and Hunan Silver, with net purchases of 604.81 million yuan and 352.97 million yuan, respectively [9] Notable Announcements - Shuaifeng Electric announced an expected net loss of 43 million to 62 million yuan for 2025, with projected revenue between 210 million to 250 million yuan [12] - Anqi Yeast plans to invest 222 million yuan in a new green manufacturing project for yeast products [13] - Construction Machinery expects a net loss of approximately 2.072 billion yuan for 2025, attributed to a downturn in the tower crane rental market [13] - Aerospace Electric anticipates a net loss of 39 million to 58 million yuan for 2025, impacted by industry overcapacity and competitive pressures [13] - Lisheng Pharmaceutical forecasts a net profit of 400 million to 440 million yuan for 2025, representing a year-on-year increase of 116.77% to 138.44% [14]

力生制药（002393）(002393.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润4亿元 至4.4亿元，同比增长116.77%-138.44%;扣除非经常性损益后的净利润1.6亿元至1.9亿元，同比增长 55.34%-84.47%。 ...

智通财经APP讯，力生制药(002393.SZ)披露2025年度业绩预告，公司预计归属于上市公司股东的净利润 4亿元至4.4亿元，同比增长116.77%-138.44%;扣除非经常性损益后的净利润1.6亿元至1.9亿元，同比增长 55.34%-84.47%。 ...

中证智能财讯力生制药（002393）1月23日晚间披露2025年度业绩预告，预计2025年归母净利润4亿元至4.4亿元，同比增长116.77%-138.44%；扣非净利润预 计1.6亿元至1.9亿元，同比增长55.34%-84.47%；基本每股收益1.5元/股-1.8元/股。以1月23日收盘价计算，力生制药目前市盈率（TTM）约为13.22倍-14.54 倍，市净率（LF）约1.17倍，市销率（TTM）约4.41倍。 以本次披露业绩预告均值计算，公司近年市盈率（TTM）图如下所示： 近年来市盈率变化情况 (倍) 350 327.17 @00 250 200 150 100 50 28:07 28.55 30825 4:86 0 2020-12-37 1 2027-12-37 022-12-37 2-06-30 2n- 公司 -{○- 行业均值 100 95 58 07 ହ 90 80 70 ed 2 60 50 45.02 44616 40 30 20 10 7.63 0 2021-12-37 1 2020-12-37 ' <022-72-37 ' 5-12-37 . -06-30 2-06-30 2n- ← ...